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Data sharing models designed to facilitate global
business provide insights for improving transborder
genomic data sharing. We argue that a flexible,
externally endorsed, multilateral arrangement,
combined with an objective third-party assurance
mechanism, can effectively balance privacy with the
need to share genomic data globally.the ‘Bermuda Principles’ [4], data sharing is now emer-The opportunities presented by data sharing
models
One of the great opportunities in the genomics era is ex-
ploring how human genes influence health, disease and
biologic pathways, and how the knowledge gained can
contribute to better health through both prevention and
therapy. Researchers collaborating globally can gather
sufficiently granular data to discover gene-environment-
disease correlations for translational research and clin-
ical application. Conducting scalable projects has been
aided by the convergence of two key developments: vast
improvements in, and access to, low-cost sequencing
technology, and the increased power and sophistication
of data analytics, driven by what has become termed ‘Big
Data’ [1]. Big Data provides a new generation of data ana-
lytics technologies that extract value from large, complex
datasets (including genome and health-related datasets) so
as to enable rapid capture, discovery and analysis [2].
The analysis, integration and translation of these diverse
types of health data present a real challenge for science
and policy. Progress in our ability to impact human health
is highly reliant on bringing genomic technologies to bear
on Big Data in ways that maximize data use, while minim-
izing duplicative effort and costs. But leveraging such* Correspondence: bartha.knoppers@mcgill.ca
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changes aimed at enhancing genomic data sharing across
borders.
Data sharing and research collaboration have become
increasingly pervasive in the genomic research commu-
nity. Moreover, funders increasingly require researchers
to have data sharing plans described in grant applica-
tions [3]. Propelled by the groundbreaking data release
policy of the human genome project (HGP), known as
ging in clinical research as well [4]. The genomic re-
search community has further fostered a culture of
collaborative data sharing through international research
consortia and public research platforms [5,6]. These are
built on the belief that combining and sharing datasets
will generate the statistical power needed to accelerate
discovery and translate research findings into clinical
practice. Also driving such collaborations are public
funding requirements to enable sharing and secondary
analyses of data and the corresponding ethical obligation
to share knowledge for the benefit of society [7,8].
While a culture of global research collaboration is
emerging, significant policy impediments to transborder
data sharing remain [9]. Given the growing interest to
combine individual-level genotype and phenotype data
to understand better the determinants of health and dis-
ease, the more realistic starting assumption is that such
data are, or might be, personal in nature. Genomic and
clinical data sharing as a practice is challenged by regu-
latory systems originally developed to protect personal
data within single jurisdictions [10]. These older data
protection regimes are no longer attuned to the evolving
paradigm of large-scale global health research, often
resulting in inefficient data flow, significant costs and
delays. For instance, in a recent literature review cata-
loguing barriers to sharing in biobanks, Colledge and
colleagues remarked that ‘the divergence of regulations
on the … transfer … of tissues and data is repeatedly
mentioned as an obstacle to international collaboration’l Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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of personal information for research purposes, many
others still do not, making inter-jurisdictional data ex-
change between research collaborators difficult, if not
impossible, to achieve.
Realizing the promise of Big Data to accelerate scien-
tific discovery and improve global health is of paramount
importance. So too is the need to respect personal priv-
acy and preserve public trust in health research [12].
Reconciling data protection laws designed to restrict
transborder data flows with the scientific needs to share
data globally is the challenge.
Scientists are not the first to face this challenge. For
over two decades, businesses driven by global competi-
tive forces have sought to derive value from personal
data and capitalize on this new form of international
currency [13]. Several models have emerged for sharing
customer and employee data between companies, sub-
sidiaries, affiliates, data processors and other organiza-
tions in different countries [14]. While none of these
models has been entirely successful, their implementation
to date offers valuable lessons for genomic researchers
equally motivated to share genomic and clinical data
across borders.
Here, we review six international data sharing models
established largely to improve data flows in global com-
merce (summarized in Table 1). We then explain how
useful insights can be drawn from each of the models to
inform how genomic and clinical data sharing can be fa-
cilitated. We use the Global Alliance for Genomics and
Health (GA4GH) as a case study to illustrate how an
organization could apply the best elements of these
models to the genomic research context. Our approach
is inspired by the guiding work conducted in the Public
Population Project in Genomics and Society (P3G) [15]
and the vision of a newly formed international group of
ethical, legal and social implications (ELSI) scholars
(called ‘ELSI 2.0’) that, together, develop innovative tools
and frameworks for enabling global, interdisciplinary
genomic research in the public interest [16].
Adequacy
The European Union’s Data Protection Directive 95/46/
EC (the ‘EU Directive’) generally prohibits exporting per-
sonal data of EU residents without consent unless the
European Commission has determined a priori that the
privacy laws of the importing country provide adequate
protection [17]. To date, only a handful of non-EU coun-
tries, such as Argentina, Canada, Israel and New Zealand,
have been granted ‘adequacy’ status under the EU Direct-
ive [18]. Adequacy in this context is a functional concept
that means that the data protection regime of the import-
ing country affords a sufficient level of protection, judged
by both the intended data processing activity itself (forexample, nature of the data, purpose and duration of the
processing operation(s)) and the legal regime or measures
applicable to the data recipient (for example, general and
sectoral rules of law, professional requirements and secur-
ity measures) [19].
The adequacy model provides strong upfront assur-
ance that privacy will continue to be protected abroad,
and, once a non-EU country obtains an adequacy desig-
nation, all data transfers from the EU to that non-EU
country are permitted. As drawbacks, however, this
model imposes the views of the ‘data export’ nation on
other countries, the process for obtaining adequacy sta-
tus can take many years, and, although the model allows
free data flows between EU and adequate non-EU coun-
tries, it does not allow sharing with countries not recog-
nized as adequate.
Safe harbor
With no comprehensive data protection law, the USA
does not meet the EU’s adequacy criteria. Given power-
ful commercial incentives to enable trade with the USA,
an alternative arrangement, known as the ‘US-EU Safe
Harbor Framework’ , was developed to allow the export
of EU data to participating US companies, notwithstand-
ing the lack of adequacy status conferred upon the USA
[20]. To enter this ‘safe harbor’ , US organizations self-
certify that they will comply with seven safe harbor prin-
ciples. Adherence is enforced through the powers of the
US Federal Trade Commission to investigate companies
for false and misleading practices. To date, over 3,000
US companies have registered in the program [21].
This model is straightforward to administer from a
regulatory perspective, and entry into the safe harbor is
based on a flexible, voluntary commitment of adherence.
As a self-certification process, however, it does not pro-
vide the objective assurance of other models. Moreover,
only a nation with sufficient economic and political
clout can negotiate such an exceptional arrangement.
That said, even nations as powerful as the USA are not
beyond ongoing scrutiny. Indeed, in March 2014, the
European Parliament backed a resolution calling for the
suspension of the US-EU Safe Harbor Framework owing
to concerns that it does not adequately protect European
citizens [22]. Should the Framework be suspended, it
will have a detrimental impact on organizations that cru-
cially depend on data exchange between the EU and the
USA.
Binding corporate rules
Binding corporate rules (BCRs) are another exceptional
means of exporting personal data outside the EU. Multi-
national corporations with pre-approved BCRs can trans-
fer personal data within their corporate entity, including
affiliates and subsidiaries in non-EU countries that do not
Table 1 Advantages and disadvantages of six transborder data sharing models
Transborder data
sharing models
Prototype Description Advantages Disadvantages
1. Adequacy EU Directive 95/46/EC,
Arts [25,26,30]
Personal data can be transferred
to a foreign jurisdiction if its
laws ensure an adequate level
of protection in comparison
with those of the exporting
jurisdiction
• Ensures that the privacy laws
of a foreign jurisdiction
provide an adequate level of
protection before personal data
are sent to that foreign
jurisdiction
• Long, slow process of
adequacy designation - very
few designations made to date
• Imposes the privacy law
regime of one jurisdiction on
those of others
• Only allows personal data to
flow from a jurisdictional hub
to the end of one spoke at a
time
• Provides upfront assurance
and confidence on a
country-wide basis
• Does not allow data-flows
‘around the wheel’
2. Safe harbor The EU-US Safe Harbor Personal data can be transferred
to a non-adequate foreign
jurisdiction (designated a ‘safe
harbor’) if organizations in the
safe harbor voluntarily self-
certify that they will comply
with mutually agreed-upon data
protection principles (for ex-
ample, access, security, data
integrity, enforcement)
• Allows personal data transfers
to a foreign jurisdiction
without adequate legislation
• Lacks transparency and strong
enforcement mechanisms
Framework
• Administratively quite simple
and well suited for small or
medium-sized business entities
• No upfront assurance or
third-party certification
provided
• Can only allow data to flow
unidirectionally from one
jurisdiction to another, not
multidirectionally or between
other countries









A multinational company can
transfer personal data to
affiliates and subsidiaries in
foreign jurisdictions without
adequacy status if it submits its
global privacy policies and
practices to a ‘lead’ data
protection authority (DPA) for
review and prior approval




• Only applies to organizations
within a single corporate entity
• Process of review and approval
is lengthy and bureaucratic
• Allows data transfers to
multiple countries at once
• Not well suited for small- or
medium-sized organizations
• Not easily scalable if many
applications are submitted for
approval to the same DPAs at
once
• Provides upfront assurance






Personal data can be transferred
from one organization to another
organization situated in a
non-adequate foreign jurisdiction
if the organizations agree to
enter into a model contract
pre-approved by the relevant
DPA(s) as providing sufficient
privacy protection
• Allows data transfers to
organizations in countries that
do not have adequacy status
• Of limited flexibility as model
contracts must be used as
they are, and any amendments
must be resubmitted to the
relevant DPAs for approval
• Multiple contracts are required
for data to flow to several
organizations or countries
• Provides upfront assurance
that agreements are ‘up to
snuff’ and will provide
sufficient protection
• Not currently suitable for
multidirectional/multiparty
flows
• Establishes grounds for
contractual liability in the
event of noncompliance
5. Accountability Canada’s PIPEDA,
Principle 4.1.3
Organizations remain
accountable for personal data in
their possession and transferred
to third-parties for processing.
The transferring organization
must use contractual or other
means to ensure that the personal
data continue to receive a
comparable level of protection
along the ‘chain’ of third-party
transfers
• Ensures comparable-level pro-
tection along the entire chain
of third-party data transfers
• No front-end assurance or
certification provided
• Requires transferring
organization to carry out due
diligence of third-parties and




• Light, flexible, not front-loaded
• Weak enforcement
mechanisms available if things
go wrong
• Focused on the ends of
privacy protection, not the
means
• Monitoring capabilities can be
limited
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and certify voluntarily participating
organizations against those
requirements. Once certified, an
organization can partake in
foreign data transfers, although
still subject to the applicable
privacy laws. Participating
jurisdictions must have a
domestic privacy regulator for
enforcement purposes
• Provides upfront assurance,
although less rigorous than
DPA-approved BCRs
• Variation of laws remains a
challenge
• Could be flexible and expedient,
depending on the efficiency of
the accountability agent
• Little experience to date of
how it works in practice
• Currently, does not include EU
countries, which remain
subject to the foreign transfer
limitations of the EU Directive
• There are some questions with
respect to the rigor of the




• Scalable mechanism capable
of handling large numbers of
applications
• Does not displace domestic
laws, but provides additional
assurance that facilitates
acceptance of foreign transfers
Six different data sharing models have been developed largely to improve data flows in global commerce: adequacy; safe harbor; binding corporate rules; model
contracts; accountability; and third-party certification. Each model by itself possesses advantages and disadvantages. In this article, we argue that a new model,
drawing from certain attributes of each, could be designed and adapted to facilitate global genomic and clinical data sharing in the Big Data era. Abbreviations:
APEC Asia-Pacific Economic Cooperation, BCR Binding Corporate Rules, DPA data protection authority, EU European Union, PIPEDA Personal Information
Protection and Electronic Documents Act.
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must submit its global policies and practices to a ‘lead’ EU
data protection authority (DPA) - typically in the country
of its European headquarters. Once the lead DPA gives its
‘stamp of approval’ , a mutual recognition scheme among
most EU member states facilitates approval by other rele-
vant DPAs [23]. To date, over 50 corporations have re-
ceived BCR approval [24].
Approved BCRs provide upfront privacy assurance and
allow data transfers between organizations in different
jurisdictions, but only if they form part of the same corpor-
ate entity. From a regulatory perspective, the BCR approval
process can be lengthy despite the mutual-recognition
scheme and is not easily scalable to handle many applica-
tions at once. Although BCRs have only been approved for
certain multinationals, the concept could, in theory, be ap-
plied to other entities, such as not-for-profit international
research consortia.
Model contracts
Model contracts are yet another mechanism created to
permit the transfer of EU personal data to non-EU coun-
tries. The European Commission can pre-approve stand-
ard contractual clauses that build in sufficient protection
for foreign transfers [25]. To date, the Commission has
approved two sets of contractual clauses for the export
of personal data outside the EU. Organizations wanting
to use these pre-approved model clauses must use them
as they are - any amendments must be submitted for ap-
proval by the relevant DPA.
Provided there are no amendments, these pre-approved
model contracts can be a quicker, more cost-effective ap-
proach of providing upfront assurance by DPAs. Model
contracts have the further advantage of permitting data
transfers outside a single corporate entity, which BCRs donot allow. Although model contracts approved to date have
been conceived as bilateral agreements, there is nothing
preventing the possibility of having multilateral agreements
between the multiple parties of a broader consortium pre-
approved by the European Commission.
Accountability
The accountability model is typified by Canada’s Personal
Information Protection and Electronic Documents Act
(PIPEDA) [26]. In contrast to the EU’s adequacy model,
which assesses jurisdictional laws based on geography,
PIPEDA focuses on the organizations involved, wherever
situated, holding them accountable for the personal data
they have, including personal data transferred to foreign
third-parties for processing. The transferring organization
must use contractual or other means to ensure that per-
sonal data continue to receive a comparable level of protec-
tion along the ‘chain’ of third-party transfers, but ultimately
remains accountable for its weakest link.
PIPEDA does not require prior approval by the relevant
DPA; instead, it provides an after-the-fact complaint mech-
anism for individuals seeking to challenge the level of pro-
tection. Arguably, this is among the most flexible models,
but the limited regulatory scrutiny might be insufficient to
secure public trust, particularly when dealing with sensi-
tive health data. Although organizations with requisite
bargaining power can dictate the privacy practices of con-
tractors and subcontractors, those of smaller size and in-
fluence are less able to do so.
Third-party certification
In 2011, the Asia-Pacific Economic Cooperation (APEC)
economies endorsed a cross-border privacy rules (CBPR)
system to facilitate data sharing in the Asia-Pacific region
[27]. To participate, economies must have a domestic
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(AA). AAs are third-party entities (either public or private)
that review, assess and, if satisfied, certify the personal
information management practices of an organization
against a series of program requirements based on the
APEC Privacy Framework. To date, three economies - the
USA, Mexico and Japan - have been accepted, and Canada
has announced its intention to participate [28]. Although
experience with this model has been limited, the APEC
Data Privacy Subgroup and experts from EU data protec-
tion authorities recently developed a practical tool (termed
a ‘referential’) that compares the CBPR system with BCRs
in an effort to facilitate inter-regional interoperability [29].
This model is flexible, scalable and provides upfront
assurance. It potentially allows many participants to
join, facilitating transborder data flows across multiple
jurisdictions at once. However, reaching common agree-
ment on framework rules, passing the rigorous upfront
scrutiny needed to gain entry, and determining which
bodies qualify as legitimate third-party certifiers can be
challenging.
Lessons for global genomic research
Given their respective limitations, none of these inter-
national data sharing models, developed largely to facili-
tate transborder data sharing in support of global business
transactions, can be wholly transposed to the genomics re-
search context. Yet, useful insights can be drawn from
each of them to inform how genomic and clinical data
sharing can be facilitated globally.
First, given the objective of accelerating statistically
significant findings by combining, analyzing and compar-
ing genomic data across as many researchers and research
institutions around the world as possible, an inclusive
multilateral arrangement would seem better suited than
discrete bilateral arrangements.
Second, a scalable model could better accommodate
increasing numbers of collaborating researchers and in-
stitutions wanting to join the data sharing arrangement
over time, without bogging down the arrangement or
imposing undue burden on the limited resources needed
to regulate entry.
Third, given the sensitive nature of genomic and clin-
ical data, providing upfront assurance before sharing
data would be crucial for building and maintaining pub-
lic trust [30]. External endorsement of the overarching
data sharing arrangement by relevant data protection
authorities or recognized third-party certification bodies
would ensure that it meets different regulatory requirements
and that researchers interested in joining comply with
common principles or rules governing the arrangement.
Fourth, a trustworthy data sharing model for genomic
and clinical data requires effective enforcement measures
in cases of noncompliance [31]. These could include dataaccess prevention, expulsion from the sharing arrange-
ment and, in appropriate cases, investigation and possible
sanction by relevant regulatory bodies.
Finally, internal ‘data user accountability’ [32] beyond
mere legal compliance is needed to hold members of the
arrangement accountable for how they use and manage
data on an ongoing basis - especially in this era of Big
Data, where it is nearly impossible to circumscribe the
purposes for collection or limit future uses [33]. Mem-
bers would be expected to assess potential harms and
benefits, adopt effective safeguards for mitigating risks
and implement robust governance processes for oversee-
ing data access and use. Such governance processes have
traditionally included policies, processes and oversight
mechanisms, but increasingly also include: participant
interfaces that give individuals greater control over their
information, ‘e-governance’ systems that emphasize the
use of technology to ensure compliance with ethical and
legal requirements, and ‘adaptive governance’ systems
that are responsive to changing conditions and allow for
greater community engagement [12].
Given the considerations above, a data sharing model
specially customized for global research consortia could
well have the following traits: a flexible, multilateral ar-
rangement, endorsed by relevant data protection author-
ities (such as BCRs or model contracts), and combined
with an objective third-party assurance mechanism that
regulates members’ entry and ongoing access (such as
accountability agents in the APEC CBPR system). Until
demonstrable evidence bears out the strengths and weak-
nesses of this and various other models (as has been pro-
posed in other settings [34]), it is useful to consider how
these suggestions could apply to a real-world case study,
namely the newly established Global Alliance for Genomics
and Health (GA4GH).A case study: the global alliance for genomics and
health
In June 2013, a broad and diverse coalition of leading
health and research organizations united with a global
mission to accelerate progress in science and medicine
through global data sharing. The GA4GH [35] was created
as an international umbrella organization to develop and
promulgate harmonized approaches (both technical and
regulatory) for the effective and responsible sharing of
genomic and clinical data across jurisdictions [36]. Cur-
rently, it has over 200 partners in more than 30 countries.
The GA4GH seeks to work collaboratively with its mem-
bership to play an active role in catalyzing data sharing
among members to advance science and improve human
health. At the same time, it works together with its mem-
bers to promote the highest standards for ethics and en-
able participant choice to share their genomic and clinical
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ingfully to the advancement of human health.
International collaborations such as the GA4GH pro-
vide a timely opportunity for imagining a global data shar-
ing arrangement based on some of the desirable traits
canvassed above. To gain acceptance by the regulatory
community and broader public, a data sharing arrange-
ment between members of the GA4GH would have to be
clear and transparent about its purpose: to improve global
health in the public interest. As an overarching ‘consor-
tium of consortia’ that includes both the for-profit and
not-for-profit sector, the GA4GH would need to have flex-
ible, multilateral arrangements in place. Whether central-
ized or federated, research initiatives using these GA4GH
arrangements could then benefit from the prior formal
endorsement by as many data protection authorities as
possible. Entry into GA4GH projects could be subject
to a scalable third-party certification process that as-
sesses interested parties against commonly recognized
principles and objective criteria. This upfront assurance
could be complemented by internal accountability mecha-
nisms for overseeing ongoing data access and use, rein-
forced by serious sanctions for noncompliance.
The GA4GH Regulatory and Ethics Working Group, of
which several of this paper’s authors are members (BMK,
ESD, EMM, JK), is actively implementing this vision of a
flexible, multilateral arrangement by developing a ‘Frame-
work for Responsible Sharing of Genomic and Health-
Related Data’ (the ‘Framework’). The Framework is incor-
porated by reference into a constitution endorsed by
GA4GH members. The Framework is founded on, and
guided by, the human-rights principles of privacy, non-
discrimination and procedural fairness [3]; it provides a
principled and practical framework for the responsible
sharing of genomic and health-related data between mul-
tiple international organizations, including the Public
Population Project in Genomics and Society (P3G), the
International Cancer Genome Consortium (ICGC), H3Af-
rica, the Biobank Standardisation and Harmonisation for
Research Excellence project (BioSHaRE) and the Inter-
national Rare Disease Research Consortium (IRDiRC).
The Framework will be elaborated by subsequent pol-
icies on particular issues such as ethical governance,
consent, privacy and security, and, in so doing, will elu-
cidate the various core elements of responsible data
sharing. The Framework and policies, particularly if en-
dorsed by multiple data protection and research-ethics
oversight-authorities across various jurisdictions, could
be used in genomic research projects around the world,
whether GA4GH-‘inspired’ or not. Recognizing diversity
of legal and ethical approaches and being responsive to
emerging issues, both the Framework and the policies
can hopefully serve as a potential model and provide
leadership in this domain for wider discussion. Throughits international collaboration, sharing of best practices
and cross-pollinating of ideas and learning, the GA4GH
serves as a powerful case study of how the best elements
from data sharing models developed largely for commercial
purposes can be applied to the genomic research context.
Concluding remarks
We believe that it is possible to protect privacy while
also enabling societal benefits that come from the use of
data. Just as Big Data is changing the way genomic sci-
ence is conducted, so too is it changing the way it must
be governed. We have discussed six transborder data shar-
ing models largely stemming from a commercial context
that might, when compared and combined, offer valuable
lessons for genomic research collaborations. The fact that
international data sharing models, however imperfect, were
able to emerge when commercial incentives were suffi-
ciently strong should offer hope for genomic researchers
equally motivated and engaged to share data for even
more socially valuable purposes.
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